Evidence map›Paper›PMID 36135377›Full record

ArticlemBio2022

Comparative Assessment of Severe Acute Respiratory Syndrome Coronavirus 2 Variants in the Ferret Model.

Joanna A Pulit-Penaloza, Jessica A Belser, Xiangjie Sun, Claudia Pappas, Nicole Brock, Troy J Kieran, Jana M Ritter, Josilene N Seixas, Joyce Jones, Poulami Basu Thakur and 6 more

Open access · goldAbstract readComparative Study
In one paragraph

Article in mBio, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Article
  6. Article
  7. Ferrets: A powerful model of SARS-CoV-2.Zoological research · 2023
    Review
  8. Animal models for COVID-19 and tuberculosis.Frontiers in immunology · 2023
    Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 1 institution in 1 country.

Joanna A Pulit-PenalozaInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Jessica A BelserInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Xiangjie SunInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Claudia PappasInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Nicole BrockInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Troy J KieranInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Jana M RitterDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Josilene N SeixasDivision of High-Consequence Pathogens and Pathology, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Joyce JonesInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Poulami Basu ThakurInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Elizabeth PuschInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Li WangInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Terrence M TumpeyInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
David E WentworthInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Bin ZhouInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.
Taronna R MainesInfluenza Division, National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Preventiongrid.416738.f, Atlanta, Georgia, USA.ORCID 0000-0002-4097-6724
Centers for Disease Control and Prevention · US

Funding

CDC HHS
6 · The paper itself

Abstract

The continued spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in humans necessitates evaluation of variants for enhanced virulence and transmission. We used the ferret model to perform a comparative analysis of four SARS-CoV-2 strains, including an early pandemic isolate from the United States (WA1), and representatives of the Alpha, Beta, and Delta lineages. While Beta virus was not capable of pronounced replication in ferrets, WA1, Alpha, and Delta viruses productively replicated in the ferret upper respiratory tract, despite causing only mild disease with no overt histopathological changes. Strain-specific transmissibility was observed; WA1 and Delta viruses transmitted in a direct contact setting, whereas Delta virus was also capable of limited airborne transmission. Viral RNA was shed in exhaled air particles from all inoculated animals but was highest for Delta virus. Prior infection with SARS-CoV-2 offered varied protection against reinfection with either homologous or heterologous variants. Notable genomic variants in the spike protein were most frequently detected following WA1 and Delta virus infection.

Indexed as

COVID-19SARS-CoV-2AnimalsFerretsHumansReinfectionRNA, ViralSpike Glycoprotein, CoronavirusRNA, ViralSpike Glycoprotein, Coronavirusairborne transmissionCOVID-19DeltaferretreinfectionSARS-CoV-2variant

Identifiers

PMID36135377
PMCPMC9600705
OpenAlexW4296613284

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.